

CLAIMS:

1. A method for delivery and retention of an active agent in one or more targeted lymph nodes, comprising:
 - a) injecting into a mammal a first composition comprising ligand conjugated to a colloid; and
 - a) injecting into said mammal a second composition comprising anti-ligand, wherein said anti-ligand binds to said ligand.
2. The method of claim 1, wherein the colloid comprises a liposome.
3. The method of claim 2, wherein the liposome comprises phospholipid.
4. The method of claim 2, wherein the liposome comprises cholesterol.
5. The method of claim 3, wherein the phospholipid comprises DPPC or DSPC.
6. The method of claim 1, wherein the ligand comprises biotin.
7. The method of claim 1, wherein the anti-ligand comprises avidin.
8. The method of claim 1, wherein the colloid is associated with an active agent.
9. The method of claim 8, wherein the active agent is chosen from the group consisting of diagnostic agents, therapeutic agents, photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, dyes for visual detection, radiosensitizers, radioprotectors, DNA, RNA, antigens, radioisotopes and neutron capture isotopes.
10. The method of claim 9, wherein the active agent is chosen from the group consisting of radioisotopes and dyes.

11. The method of claim 9, wherein the active agent is chosen from the group consisting of diagnostic agents and dyes for visual detection
12. The method of claim 9, wherein the active agent is chosen from the group consisting of photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, radiosensitizers, radioprotectors, DNA, RNA, and neutron capture agents.
13. The method of claim 1, wherein the anti-ligand comprises an active agent.
14. The method of claim 1, wherein the ligand comprises biotin and the anti-ligand comprises avidin.
15. A method for detecting one or more sentinel lymph nodes comprising:
 - a) injecting in the vicinity of a tumor in a mammal a first composition comprising ligand conjugated to a colloid; and
 - b) injecting into said mammal a second composition comprising anti-ligand, wherein said anti-ligand binds to said ligand
16. The method of claim 15, wherein the colloid comprises an active agent.
17. The method of claim 16, wherein the active agent is chosen from the group consisting of radioisotopes and dyes.
18. The method of claim 15, wherein the anti-ligand comprises a detection agent.
19. The method of claim 18, wherein the detection agent comprises a radioisotope or dye.
20. A kit for delivering and retaining an active agent in one or more lymph nodes, comprising:
 - a) a first composition comprising ligand conjugated to a colloid; and
 - b) a second composition comprising anti-ligand.

21. The kit of claim 20, wherein the colloid comprises an active agent.
22. The kit of claim 20, wherein the anti-ligand comprises an active agent.
23. The kit of claim 21, wherein the anti-ligand comprises an active agent
24. The kit of claim 20, further comprising a means for delivering the compositions to a mammal.
25. A composition comprising:
 - a) ligand conjugated to colloid; and
 - b) anti-ligand.
26. The composition of claim 25, wherein the colloid comprises an active agent.
27. The composition of claim 25, wherein the anti-ligand comprises an active agent.
28. The composition of claim 25, wherein the colloid comprises:
 - a) glutathione;
 - b) ^{99m}Tc -HMPAO; and
 - c) blue dye.